Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trialRandomized Controlled Trial Published on 2023-03-012023-07-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] Antiviral clinical trial COVID-19 Lopinavir Outpatient Ritonavir. [DOI] 10.1016/j.ijid.2022.12.028 PMC 바로가기 [Article Type] Randomized Controlled Trial
Morning SARS-CoV-2 Testing Yields Better Detection of Infection Due to Higher Viral Loads in Saliva and Nasal Swabs upon WakingArticle Published on 2022-12-212023-07-10 Journal: Microbiology Spectrum [Category] COVID19(2023년), [키워드] ambulatory analytical sensitivity circadian rhythm COVID-19 diagnostic Outpatient pandemic sample collection Screening specimen collection Viral load. [DOI] 10.1128/spectrum.03873-22 PMC 바로가기
SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2Article Published on 2022-12-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome All participant BA.1 BA.2 Booster vaccine caused collected comparable composed coronavirus coronavirus disease COVID-19 Day Diagnosis dose elapsed had no Infection log median median age nasopharyngeal specimen omicron Omicron variant Outpatient Patient reached retrospective RNA SARS-CoV-2 SARS-CoV-2 RNA Support symptom onset TaqPath Thermo Fisher Scientific time Transmissibility upper respiratory tract URT vaccination schedule Vaccine vaccine dose Viral load Viral load. viral RNA load was used [DOI] 10.1002/jmv.28079 PMC 바로가기
Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trialClinical Trial Published on 2022-12-012023-07-10 Journal: EBioMedicine [Category] COVID19(2023년), [키워드] Artesunate-amodiaquine Favipiravir + nitazoxanide Outpatient Pyronaridine-artesunate SARS-CoV-2 Sofosbuvir-daclatasvir. [DOI] 10.1016/j.ebiom.2022.104322 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022Article Published on 2022-11-012023-07-11 Journal: Influenza and Other Respiratory Viruses [Category] COVID19(2023년), [키워드] COVID‐19 Outpatient vaccine effectiveness. [DOI] 10.1111/irv.13029 PMC 바로가기
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sourcesArticle Published on 2022-10-292022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 Antibody titer CCP collected convalescent plasma COVID-19 Donor dose effective geometric geometric mean titer Immune escape Immunocompromised implication Infection lesson monoclonal antibodies monoclonal antibody mRNA vaccine neutralization neutralize Neutralizing Neutralizing antibody titer omicron Outpatient pandemic plasma plasma activity provide recipients reduction representing SARS-CoV-2 variant sera subject therapeutic Therapies uninfected vaccinee variant variants of concern [DOI] 10.1038/s41467-022-33864-y PMC 바로가기
Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 – United States, January-July 2022Article Published on 2022-10-282022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] 치료제, [키워드] African American Alaska Antiviral Antiviral treatment antivirals Asian black booster doses Care COVID-19 COVID-19 in patient COVID-19 patient COVID-19 treatments COVID-19 vaccination disparity drug EHR Emergency use authorization EUA facilitate food Health help high risk highest Hispanic patient Immunocompromised less mAb medication Mild-to-moderate molnupiravir monoclonal antibody Native outcomes Outpatient Patient patient groups patients Paxlovid PROTECT Racial Remdesivir report risk seeking severe COVID-19 treated Treatment United States were used White patients [DOI] 10.15585/mmwr.mm7143a2 PMC 바로가기
Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 OutpatientsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 치료기술, 치료제, [키워드] acting acute respiratory syndrome added Administered administration Amplicon sequencing analyses Analysis antibody Antiviral antiviral property antiviral strategy applied Bacteria benefit Care chills collected Combined coronavirus coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients detectable Diagnosis diarrhea double-blind dried blood spot eligible evaluated Fever Health hospital Hospitalization infected with SARS-CoV-2 Lactobacillaceae lactobacilli Microbiome modulation multifactorial nasopharyngeal viral load nose-throat swab online questionnaire Outpatient Pain Patient per-protocol analysis Placebo placebo-controlled trial positive potential mechanism practitioners qPCR quantitative PCR Randomized reduce reducing reported reported symptom respiratory tract infection respiratory viral disease SARS-CoV-2 selected sequence severity significantly spray strain Symptom symptom resolution the patient the placebo group therapy Throat throat spray. Treatment Trial trials upper respiratory tract Vaccines variant Viral diseases viral infection Viral load was performed [DOI] 10.1128/spectrum.01682-22 PMC 바로가기
Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric studyArticle Published on 2022-10-212022-11-15 Journal: Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome addition Analysis analyzed Antibody titer attenuate Baricitinib BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 vaccine Combination controls coronavirus coronavirus disease COVID-19 COVID-19 vaccine disease domain dose Glucocorticoids healthy volunteer humoral immune response immunomodulatory Immunosuppressant immunosuppressants immunosuppressive immunosuppressive agent Immunosuppressive medication impair inhibitor inhibitors interleukin-17 interleukin-6 investigated Japanese Kagawa methotrexate much lower Necrosis of BNT162b2 Outpatient Patient patients treated reduced rheumatic disease SARS-CoV-2 SARS-CoV-2 spike protein second dose serum serum antibody significantly significantly lower Spike protein the patient therapeutic agent Treatment university Vaccine [DOI] 10.1097/MD.0000000000031288 PMC 바로가기
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19Article Published on 2022-10-192022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% CI Administered administration Adverse affected analysed antiviral therapy Antiviral treatment ARMS baseline changed Combination combination therapy concentrations conducted coronavirus 2 COVID-19 COVID-19 pandemic Day Dose escalation doses double-blind double-blind trial drug level effective Efficacy evaluate the effect event Favipiravir healthy Interaction Lopinavir-ritonavir measure monotherapy Odds ratio Outpatient participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial placebos plasma primary analysis Primary outcome provided randomised recruited reduced respiratory SARS-CoV-2 SARS-CoV-2 viral load significant interaction significantly study population symptom onset the mean trajectory Treatment undetectable United Kingdom Viral load virus [DOI] 10.1371/journal.pmed.1004120 PMC 바로가기